MedTrace Logo

Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis

NCT04324918 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2020-03-27

No results posted yet for this study

Summary

Efficacy and safety of HCP1102 in patients with perennial allergic rhinitis :

A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial

Conditions

  • Perennial Allergic Rhinitis

Interventions

DRUG

HCP1102

The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.

DRUG

HGP1408

The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Kyung-Su Kim, M.D., Ph.D. · Gangnam Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-23
Primary Completion
2019-06-24
Completion
2019-06-24

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04324918 on ClinicalTrials.gov